Peptide–Drug Conjugates: The Homing-Missile Idea and Its Uneven Record
Peptide drug design
A peptide–drug conjugate is a homing peptide, a linker and a cytotoxic payload — a smaller, cheaper answer to the antibody–drug conjugate. The idea is twenty years old and the engineering is elegant. The clinical record is not. Strip away the press releases and the scoreboard reads: one cytotoxic conjugate reached US approval and lost it, one genuine peptide conjugate succeeded by swapping the chemical warhead for a radioisotope, and the most-cited recent success in the category is not a peptide at all.
The three-module design of peptide-drug conjugates
Every conjugate in this class is built the same way: a targeting peptide that recognises something enriched on the tumour cell, a linker, and a payload potent enough to matter at the tiny quantities that actually arrive. Homing peptides are short — typically five to thirty residues, and cell-targeting sequences can be as short as three to fourteen. That brevity is the entire value proposition against an antibody, and the entire liability.
The advantages are real. Peptides are made by chemical synthesis rather than cell culture, so manufacturing is simpler and scale-up cheaper. They diffuse into tumour tissue that a 150-kilodalton immunoglobulin never reaches. They provoke less of an immune response.
The linker is where the design actually lives
Getting the conjugate to the cell is only half the problem; releasing the drug in the right place is the other half. Cleavable linkers exploit a difference between the outside of a cell and the inside of a lysosome. A valine–citrulline sequence is cut by cathepsin B; a hydrazone is stable at plasma pH 7.4 and hydrolyses in acidified endosomes; a disulfide is reduced by glutathione, which sits around a thousand times more concentrated inside a cell than outside.
Non-cleavable linkers do the opposite, releasing payload only when the whole construct is proteolysed — and the released species keeps a charged amino-acid adduct attached. That single chemical fact is what determines whether the drug can leave the cell it was delivered to and kill neighbours that never expressed the target. It is worth noting the bystander literature comes from antibody conjugates; the principle transfers, but the primary data were not generated in peptides.
Why the size that helps also hurts
Peptides in the glomerulus are filtered and not reabsorbed below roughly 25 kilodaltons, and a conjugate at 2 to 20 kilodaltons sits comfortably under that. The measured consequences are stark: reported terminal half-lives for clinical-stage conjugates run from around 0.3 hours to a few hours. The exposure problem compounds a second one, proteolysis — native somatostatin survives two to three minutes in plasma, while octreotide, stabilised with a D-amino acid and a shortened cyclic scaffold, survives well over an hour. Nearly every trick in half-life extension and macrocyclisation exists to fight this.
There is a third problem, less discussed because it is hard to quantify. Antibody targets can be extraordinarily dense: HER2 reaches roughly two million copies per tumour cell against about twenty thousand on normal tissue, and internalisation-based delivery is generally thought to need several thousand receptors per cell. Comparable per-cell densities for the peptide receptors these conjugates aim at are simply not reported in the literature. The targeting arm may be weaker than the concept implies, and nobody has published the number that would settle it.
What actually happened in the clinic
Melflufen: approved, withdrawn, contested
Melflufen received accelerated approval in February 2021 for relapsed multiple myeloma. In October 2021 the sponsor asked to withdraw it after the confirmatory trial showed a hazard ratio for overall survival of 1.104 — and then, in January 2022, rescinded that request, forcing FDA into a contested expedited-withdrawal proceeding. An advisory committee voted 14 to 2 against, and the approval was withdrawn effective 23 February 2024. FDA's notice states the trial failed to show progression-free survival superiority and showed lower median overall survival; the trial's own publication reported a progression-free survival advantage. That disagreement between regulator and publication is worth knowing about rather than resolving in one direction.
The deeper irony: melflufen is not a homing conjugate at all. It is an alkylator attached to a lipophilic peptide that enters cells by passive diffusion and is unmasked by intracellular aminopeptidases. Its selectivity is enzymatic, not receptor-mediated. The one cytotoxic conjugate that reached US approval did not test the homing hypothesis. And it remains authorised in the European Union today.
Lutathera: the one that works
Lutathera is the clearest genuine peptide conjugate on the market. Its own label describes it as a cyclic peptide linked through a chelator to a radionuclide — the peptide being a somatostatin analogue that homes to somatostatin receptors on neuroendocrine tumours. Approved for adults in 2018 and extended to patients aged twelve and over in April 2024, it solved the exposure problem by carrying a payload that does not need long residence to do damage. That whole lane has its own story, told in our article on peptide receptor radionuclide therapy; the taxonomy is contested, with at least one recent review arguing radionuclide therapy should simply be treated as a specialised subclass of peptide–drug conjugates.
Pluvicto: widely counted, not a peptide
Pluvicto is frequently listed among peptide conjugate successes. Its label calls it a PSMA-binding ligand bound to a DOTA chelator, with a molecular mass of 1,216 daltons and no peptide sequence — the targeting element is a glutamate–urea small molecule. It is a radioligand therapy, and the distinction matters if you are trying to judge whether peptide homing works. Approved in March 2022, its label was expanded in March 2025 and again in July 2026. The difference between it and Lutathera is a clean illustration of what separates a peptide drug from a small molecule: same isotope, same chelator, entirely different targeting chemistry.
The pipeline is thinner than it looks
Zelenectide pevedotin, a bicyclic peptide carrying MMAE and a direct descendant of phage display chemistry, was deprioritised by its sponsor in March 2026 after regulatory feedback that the pivotal trial design was no longer an acceptable approval path; two trials were closed to further enrolment and a third was converted from a registrational study to a randomised phase 2. ANG1005, a paclitaxel conjugate designed to cross the blood–brain barrier, has a phase 3 trial registered since 2018 whose registry record still reads "not yet recruiting" and has not been updated since April 2023. Zoptarelin doxorubicin completed its phase 3 in 2018 and missed on both survival endpoints.
As of August 2026, a registry search for peptide–drug conjugates in phase 3 returns nothing actively enrolling. That is the honest state of the field, and it is not what the review literature's framing implies.
Where the idea still has room
None of this means peptide targeting is a dead end. The two conjugates that worked both solved the exposure problem the same way — by carrying a payload whose damage is done on contact, not accumulated over days. That points somewhere specific: radionuclides, and payloads with very steep concentration–effect relationships, rather than conventional tubulin poisons borrowed from antibody conjugates.
Metabolic peptides are being explored as homing arms too, though only in animals so far; published work attaching payloads to GLP-1 has used metabolic cargo such as oestrogen or dexamethasone rather than cytotoxins, and the only GLP-1-receptor-targeted conjugates in humans are diagnostic imaging agents. That is a different ambition from the one this field started with. It is also, on the current evidence, a more realistic one.
Frequently asked questions
What is the difference between a PDC and an ADC?
Size and targeting element. An antibody–drug conjugate uses a full immunoglobulin of roughly 150 to 160 kilodaltons; a peptide conjugate uses a short peptide, usually quoted at 2 to 20 kilodaltons for the whole construct. The peptide penetrates tissue better and clears far faster. Note that even the size range is not fully agreed across reviews.
Is peptide receptor radionuclide therapy a peptide–drug conjugate?
Structurally yes — targeting peptide, chelator linker, payload. It is usually classified separately because the payload is radiation rather than a chemical toxin and the regulatory pathway is different. Some recent reviews argue that separation is historical rather than principled.
Do peptide conjugates use cell-penetrating peptides?
Sometimes, but that is a different mechanism. A homing peptide seeks a receptor enriched on the target cell; a cell-penetrating peptide crosses membranes fairly indiscriminately. Mixing the two ideas is a common source of confusion about how selective any given construct really is.
Why do these drugs have such complicated names?
Because conjugate nomenclature stacks stems: the targeting element, the linker and the payload each contribute. "Zelenectide pevedotin" and "lutetium Lu 177 vipivotide tetraxetan" are both parsed that way. The naming rules have their own logic.
References
- Fu C, Yu L, Miao Y, et al. Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B 2023;13(2):498–516. PMC9978859
- Heh E, Allen J, Ramirez F, et al. Peptide Drug Conjugates and Their Role in Cancer Therapy. Int J Mol Sci 2023;24(1):829. PMC9820985
- Final Decision on Withdrawal of PEPAXTO (melphalan flufenamide). Federal Register 89 FR 27766, 18 April 2024. federalregister.gov
- LUTATHERA (lutetium Lu 177 dotatate) US prescribing information, 2024. accessdata.fda.gov
- PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) US prescribing information. accessdata.fda.gov
- Pepaxti (melphalan flufenamide) — European Medicines Agency EPAR. ema.europa.eu
- ANG1005 in Leptomeningeal Disease From Breast Cancer (ANGLeD), NCT03613181. clinicaltrials.gov
Informational only — not medical advice. This article summarises published research and regulatory documents about investigational and approved oncology products; it is not treatment guidance. Consult a qualified healthcare professional. Intended for readers 21+.